Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials

HIGHLIGHTS

• who: Marie-Nou00eblle Billard from the Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children`s Hospital, University Medical Center Utrecht, The Netherlands have published the paper: Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials, in the Journal: (JOURNAL)
• what: The authors aimed to illustrate the impact of year-to-year variation in attack rates on the likelihood of demonstrating vaccine efficacy (VE).

SUMMARY

Phase III vaccine trials are of critical importance to provide pivotal evidence to decide whether the benefits of . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.